The Prognostic Value of the Prognostic Nutritional Index in Patients with Sarcoidosis
Keywords:
Sarcoidosis, Prognostic nutritional index, RelapseAbstract
Background: Sarcoidosis is a heterogeneous multisystem granulomatous disease with an unpredictable clinical course. Reliable biomarkers for predicting relapse remain limited. The Prognostic Nutritional Index (PNI), reflecting systemic inflammation and immunonutritional status, has emerged as a prognostic marker in various inflammatory and pulmonary diseases. However, its role in sarcoidosis has not been sufficiently clarified. This study aimed to investigate the association between baseline PNI levels and relapse in patients with sarcoidosis.
Methods: This retrospective single-center study included 302 adult patients diagnosed with sarcoidosis between January 2015 and January 2025. Baseline laboratory parameters, including serum albumin, lymphocyte count, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR), were recorded. PNI was calculated as: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm³). The primary outcome was disease relapse during follow-up. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive performance of baseline PNI.
Results: Relapse occurred in 52 patients (17.2%) during follow-up. Patients who developed relapse had significantly lower baseline albumin levels, lymphocyte counts, and PNI values, and significantly higher CRP, NLR, and PLR levels (all p<0.01). Baseline PNI demonstrated excellent discriminative ability for predicting relapse, with an area under the curve (AUC) of 0.922 (95% CI: 0.887–0.957, p<0.001). A cutoff value of ≤39.25 yielded a sensitivity of 94.2% and a specificity of 82.8%.
Conclusion: Lower baseline PNI values are strongly associated with relapse in patients with sarcoidosis and show excellent predictive performance. As a simple, inexpensive, and widely available biomarker reflecting both inflammatory burden and immune competence, PNI may serve as a practical tool for risk stratification and individualized follow-up in clinical practice. Prospective multicenter studies are warranted to validate these findings.
Keywords: Sarcoidosis, Prognostic nutritional index, Relapse
References
1. Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, Abston E, Bernstein RC, Blankstein R, Chen ES: Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. American journal of respiratory and critical care medicine 2020, 201(8):e26-e51.
2. Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA: ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal 2021, 58(6).
3. Miedema J, Cinetto F, Smed-Sörensen A, Spagnolo P: The immunopathogenesis of sarcoidosis. Journal of Autoimmunity 2024, 149:103247.
4. Wu Q, Ding W, You D, Ji Y, Wang S, Jiang D, Huang L, Xu W, Li L, Xu J: Prognostic nutritional index, sarcopenia, and risk of mortality: a national population-based study. Nutrition & Metabolism 2025, 22(1):106.
5. Kudeken N: Prognostic Nutritional Index: A Comprehensive Review Across Clinical Specialties. Clinical Nutrition Open Science 2025.
6. Masoud HH, Ali AM, AbdelWahab F, Abdel-Hamid HM: Novel biomarkers for the assessment of disease activity in patients with sarcoidosis: a case-control study. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 2023, 40(2):e2023017.
7. Miedema JR, de Jong LJ, Kahlmann V, Bergen IM, Broos CE, Wijsenbeek MS, Hendriks RW, Corneth OB: Increased proportions of circulating PD-1+ CD4+ memory T cells and PD-1+ regulatory T cells associate with good response to prednisone in pulmonary sarcoidosis. Respiratory Research 2024, 25(1):196.
8. Onyilmaz T, Argun Baris S, Kaya H, Pehlivan AZ, Albayrak H, Aktoprak SN, Boyaci H, Basyigit I: Predictive Impact of Hematological and Biochemical Parameters on the Clinical Course of Sarcoidosis. Diagnostics 2025, 15(19):2501.
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
